Biocon Delivers Double-Digit Growth in Q4 as Biosimilars Lead Revenue Gains

Biocon Limited ( (IN:BIOCON) ) has issued an update.

Biocon reported consolidated Q4FY26 total income of Rs 4,569 crore, with operating revenue of Rs 4,517 crore and EBITDA rising 29% year-on-year to Rs 1,073 crore, delivering an EBITDA margin of 23%. Net profit before exceptional items grew 64% to Rs 179 crore, supported by strong contributions from biosimilars and generics despite the absence of last year’s one-time lenalidomide sales.

For FY26, Biocon posted total income of Rs 17,270 crore and EBITDA of Rs 3,798 crore, with net profit before exceptional items at Rs 436 crore, underscoring sustained profitability. Segmentally, biosimilars revenue rose 12% to Rs 2,756 crore, generics grew 13% on a comparable basis to Rs 847 crore, and CRDMO arm Syngene increased 2% to Rs 1,037 crore, while the company maintained significant R&D investment at 8% of revenue excluding Syngene.

More about Biocon Limited

Biocon Limited is an innovation-led global biopharmaceutical company based in Bengaluru, focusing on biosimilars, generic formulations and contract research and manufacturing services. The company operates across biosimilars, generics and CRDMO segments, with a growing presence in regulated markets and a strategic emphasis on R&D-driven biologics.

Average Trading Volume: 216,783

Technical Sentiment Signal: Buy

Current Market Cap: 616.6B INR

Learn more about BIOCON stock on TipRanks’ Stock Analysis page.